Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298747 | 0.83 | HTR2A (0.41) | SMN1; SMN2POLBHTR2AHTR2CHTR2B | |
| SCHEMBL2357556 | 0.79 | HTR2A (0.38) | SMN1; SMN2POLBHTR2AHTR2CHTR2B | |
| SCHEMBL2300018 | 0.78 | HTR2A (0.36) | ALDH1A1POLBHTR2AHTR2CHTR2B | |
| Ammonia Solution, Strong SCHEMBL27277144 | 0.77 | CYP1A2 (0.51) | SMN1; SMN2MEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL16026451 | 0.77 | GFER (0.47) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL7372558 | 0.77 | MAPT (0.43) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5674603 | 0.77 | MAPT (0.50) | SMN1; SMN2MAPTALDH1A1LMNAMAPK1 | |
| SCHEMBL31013547 | 0.77 | PRKCQ (0.52) | SMN1; SMN2MEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL31343918 | 0.76 | SMN1; SMN2 (0.62) | SMN1; SMN2MEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL9983692 | 0.76 | MAPT (0.44) | SMN1; SMN2KMT2AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421204-B2 | Oligomer modified diaromatic substituted compounds | NEKTAR THERAPEUTICS (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160143904-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| US-9226970-B2 | Oligomer modified diaromatic substituted compounds | NEKTAR THERAPEUTICS (US) | 2016-01-05 | — | — | US | disclosed |
| US-20130040961-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011103559-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040961-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | PCNA, DNPEP, POLI | SMN1; SMN2 3551/4885MEN1 4358/4885KMT2A 2559/4885 |
| US-20160143904-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | HLA-DRB1, NOD2, DCX | SMN1; SMN2 1127/4885MEN1 681/4885KMT2A 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.